The effect of the combination of estetrol and drosperinone on the quality of life and sexual function of women
- Authors: Karakhalis L.Y.1,2, Tikhaya V.R.2, Chervonnaya I.Y.3, Efremenko Y.S.1, Khalafyan A.A.4
-
Affiliations:
- Kuban State Medical University, Ministry of Health of Russia
- Regional Clinical Hospital No. 2, Ministry of Health of the Krasnodar Region
- Yekaterininskaya Clinic LLC
- Kuban State University, Ministry of Science and Higher Education of the Russian Federation
- Issue: No 2 (2024)
- Pages: 118-122
- Section: Exchange of Experience
- URL: https://journals.eco-vector.com/0300-9092/article/view/631362
- DOI: https://doi.org/10.18565/aig.2024.1
- ID: 631362
Cite item
Open Access
Access granted
Abstract
Objective: To study the effect of an oral contraceptive containing estetrol 15mg and drosperinone 3mg (Esteretta) on the sexual function and the quality of life in women of reproductive age.
Materials and methods: A total of 40 women were examined whose average age was 29.5±4.2 years; they were administered a combined oral contraceptive (COC) containing estetrol 15 mg and drospirenone 3 mg. Before taking the medication and six months after it, a survey was conducted on the issues of the Female Sexual Function Index (FSFI) and on the SF-36 (Short Form Medical Outcomes Study) questionnaire about the quality of life.
Results: There was an improvement in the following parameters of quality of life in six months: PF (physical functioning) increased by 14.45 scores; role physical (RP) increased by 34.5 scores; perception of bodily pain (BP) decreased; initially low score of general health (GH) increased from 52 scores to 77.5 scores; vitality (VT) increased by 11 scores; social functioning (SF) increased by 6 scores; role emotional (RE) increased by 38 scores; low parameters of mental health which were associated with the presence of depression, anxiety, and mental ill-being increased by 18 scores. According to the results of FSFI, the number of women without difficulty in lubrication increased significantly, the number of women who had orgasm increased, and number of patients with discomfort and pain during sexual intercourse decreased.
Conclusion: The combined oral contraceptive containing estetrol 15 mg and drospirenone 3 mg significantly improved the quality of life and affected the clinical manifestations of sexual disorders.
Full Text
About the authors
Lyudmila Yu. Karakhalis
Kuban State Medical University, Ministry of Health of Russia; Regional Clinical Hospital No. 2, Ministry of Health of the Krasnodar Region
Author for correspondence.
Email: lomela@mail.ru
ORCID iD: 0000-0003-1040-6736
Dr.Med. Sci., Professor, Professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Continuing Education and Professional Retraining of Specialists, obstetrician-gynecologist
Russian Federation, 350063, Krasnodar, Mitrofana Sedina str., 4; 350007, Krasnodar, Pobeda Square, 1Victoria R. Tikhaya
Regional Clinical Hospital No. 2, Ministry of Health of the Krasnodar Region
Email: lomela@mail.ru
ORCID iD: 0000-0001-7174-6529
obstetrician-gynecologist
Russian Federation, 350012, Krasnodar, st. Red Partisans, 6/2Irina Yu. Chervonnaya
Yekaterininskaya Clinic LLC
Email: lomela@mail.ru
ORCID iD: 0009-0000-8695-5219
PhD, obstetrics gynecologist
Russian Federation, 350022, Krasnodar, st. Geroya Yatskova, 22Yuliya S. Efremenko
Kuban State Medical University, Ministry of Health of Russia
Email: yuliya2397@mail.ru
ORCID iD: 0009-0008-4745-1411
Clinical Resident, Department of Obstetrics, Gynecology and Perinatology, Faculty of Continuing Education and Professional Retraining of Specialists
Russian Federation, 350063, Krasnodar, Mitrofana Sedina str., 4Aleksan A. Khalafyan
Kuban State University, Ministry of Science and Higher Education of the Russian Federation
Email: statlab@kubsu.ru
ORCID iD: 0000-0003-2324-3649
Dr.Tech. Sci., Professor at the Department of Data Analysis and Artificial Intelligence FPM
Russian Federation, 350040, Krasnodar, Stavropolskaya str., 149References
- United Nations DoEaSA, Population Division. Contraceptive use by method 2019: data booklet. (ST/ESA/SERA/435). 2019.
- Foidart J.M., Gemzell-Danielsson K., Kubba A., Douxfils J., Creinin M.D., Gaspard U. The benefits of esterol addition to drosperinone for contraception. AJOG Glob. Rep. 2023; 3(4): 100266. https://dx.doi.org/10.1016/ j.xagr.2023.100266.
- Hagen A.A., Barr M., Diczfalusy E. Metabolism of 17-beta-oestradiol-4-14-C in early infancy Acta Endocrinol. (Copenh). 1965; 49: 207-20.
- Abot А., Fontaine C., Buscato M., Solinhac R., Flouriot G., Fabre A. et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol. Med. 2014; 6(10): 1328-46. https://dx.doi.org/10.15252/emmm.201404112.
- Arnal F., Lenfant F., Metivier R., Flouriot G., Henrion D., Adlanmerini M. et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol. Rev. 2017; 97(3): 1045-87. https://dx.doi.org/ 10.1152/physrev.00024.2016.
- Foidart J.M., Gaspard U., Pequeux C., Jost M., Gordenne V., Tskitishvili E. et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Daz Brinton R., Genazzani A.R., Simoncini T., Stevenson J.C., eds. Sex steroids' effects on brain, heart and vessels. vol.6: Frontiers in gynecological endocrinology. Basel Switzerland: Springer International Publishing; 2019.
- Guivarc'h E., Buscato M., Guihot A.L., Favre J., Vessières E., Grimaud L. et al. Predominant role of nuclear versus membrane estrogen receptor alpha in arterial protection: implications for estrogen receptor alpha modulation in cardiovascular prevention/safety. J. Am. Heart Assoc. 2018; 7(13): e008950. https://dx.doi.org/10.1161/JAHA.118.008950.
- Сухих Г.Т., Прилепская В.Н., Аганезова Н.В., Андреева Е.Н., Баранов И.И., Долгушина Н.В., Зароченцева Н.В., Карахалис Л.Ю. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015 ». М.; 2023. [Sukhikh G.T., Prilepskaya V.N., Aganezova N.V., Andreeva E.N., Baranov I.I., Dolgushina N.V., Zarochentseva N.V., Karakhalis L.Yu. National medical criteria for the acceptability of contraception methods. Adapted document "WHO Medical Eligibility Criteria for the Use of Contraceptive Methods, 5th Edition, 2015." M.; 2023. (in Russian)].
- Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide. The Health Institute, New England Medical Center. Boston, Mass.1993.
- Карахалис Л.Ю., Захарова Е.С., Халафян А.А., Козыр Л.Н., Пенжоян Г.А. Гиперандрогенная дермопатия в практике акушера-гинеколога. Вопросы гинекологии, акушерства и перинатологии. 2022; 21(6): 131-8. [Karakhalis L.Yu., Zakharova E.S., Khalafyan A.A., Kozyr L.N., Penzhoyan G.A. Hyperandrogenic dermopathy in the practice of obstetrician-gynecologists. Gynecology, Obstetrics and Perinatology. 2022; 21(6): 131-8. (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2022-6-131-138.
- Аполихина И.А., Прилепская В.Н., Горбунова Е.А., Межевитинова Е.А., Бычкова А.Е. Эстетрол – новая ступень комбинированной гормональной контрацепции. Акушерство и гинекология. 2023; 3: 134-40. [Apolikhina I.A., Prilepskaya V.N., Gorbunova E.A., Mezhevitinova E.A., Bychkova A.E. Estetrol – a new stage of combined hormonal contraception. Obstetrics and Gynecology. 2023; (3): 134-40. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.72.
- Акиньшина С.В., Колода Ю.А. Особенности влияния нового контрацептива с эстетролом на профиль тромботической безопасности гормональной контрацепции. Акушерство и гинекология. 2022; 10: 159-68. [Akinshina S.V., Koloda Yu.A. The effect of a new contraceptive with estetrol on the thrombotic safety profile of hormonal contraception. Obstetrics and Gynecology. 2022; (10): 159-68. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.10.159-168.
Supplementary files
